2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime
Rathod S, McManus D, Rivera-Vinas J, Topal J, Martinello R. 2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime. Open Forum Infectious Diseases 2019, 6: s823-s824. PMCID: PMC6810941, DOI: 10.1093/ofid/ofz360.2063.Peer-Reviewed Original ResearchPiperacillin/tazobactamClostridioides difficile infectionMultivariate logistic regression modelCDI riskHealthcare-associated infectionsPTZ exposureLogistic regression modelsHospital admissionDifficile infectionΒ-lactam/β-lactamase inhibitorsCharlson Comorbidity Index scoreCommon healthcare-associated infectionsYale-New Haven HospitalComorbidity Index scoreAntibiotic stewardship effortsObservational cohort studyAntibiotic-associated diarrheaNew Haven HospitalFrequency of testingAnti-pseudomonal cephalosporinsCephalosporin therapyCohort studyΒ-lactamase inhibitorsAntibiotic therapySuppression therapy